"The U.S. Food and Drug Administration today expanded the approved use of Xgeva (denosumab) to treat adults and some adolescents with giant cell tumor of the bone (GCTB), a rare and usually non-cancerous tumor.
GCTB generally occurs in a"...
- Patient Information:
Details with Side Effects
The buffer-stabilized pancreatic enzymes in PANCRECARB® (pancrelipase) Delayed-Release are enteric-coated with a gastric acid resistant polymer to protect the enzymes during gastric transit into the duodenum.
After being swallowed, the gelatin capsules dissolve in the gastric juice within minutes and the released microspheres disperse with food in the stomach. Upon passing into the duodenum, the enteric-coated PANCRECARB® (pancrelipase) microspheres are activated at approximately pH 5.5, discharge their digestive enzymes and the released digestive enzymes help to re-establish the natural digestive conditions in the intestine.
The digestive enzymes in PANCRECARB® (pancrelipase) act locally in the gastrointestinal tract.
Once the digestive enzymes accomplish their catalytic function to hydrolyze food, the digestive enzymes may be inactivated by anti-enzymes which are secreted by the intestinal mucosa or digested by proteases. The digested enzyme fragments may be absorbed from the intestine and subsequently excreted into the urine. The inactivated enzymes are excreted in the feces.
Last reviewed on RxList: 1/20/2009
This monograph has been modified to include the generic and brand name in many instances.
Additional Pancrecarb Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.